乳腺神经内分泌癌<sup>99</sup>Tc<sup>m</sup>-MIBI显像表现一例

龙再颖; 赵燕霞; 孙达; 龙再颖; 赵燕霞; 孙达

doi:10.3760/cma.j.issn.1673-4114.2016.04.016

[1]

依荷芭丽·迟, 姜文昌, 杜丰, 等.神经内分泌瘤252例临床分析[J].中华肿瘤杂志, 2013, 35(1): 67-70.DOI:10.3760/cma.j.issn.0253-3766.2013.01.015.
Chi Yi, Jiang WC, Du F, et al.Neuroendocrine tumors:analysis of 252 cases[J].Chin J Oncol, 2013, 35(1): 67-70. doi: 10.3760/cma.j.issn.0253-3766.2013.01.015.

[2]

Santhanam P, Chandramahanti S, Kroiss A, et al.Nuclear imaging of neuroendocrine tumors with unknown primary:why, when and how?[J].Eur J Nucl Med Mol Imaging, 2015, 42(7): 1144-1155.DOI:10.1007/s00259-015-3027-4.

[3]

Ambrosini V, Morigi JJ, Nanni C, et al.Current status of PET imaging of neuroendocrine tumours([¹⁸F]FDOPA, [⁶⁸Ga]tracers, [¹¹C]/[¹⁸F]-HTP)[J].Q J Nucl Med Imaging, 2015, 59(1): 58-69.

[4]

Carreras C, Kulkarni HR, Baum RP.Rare metastases detected by ⁶⁸Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors[J].Recent Results Cancer Res, 2013, 194:379-384.DOI:10.1007/978-3-642-27994-2_20.

[5]

Caobelli F, Pizzocaro C, Zorzi F, et al.¹⁸F-FDG PET/CT presentation in a patient diagnosed with large cell neuroendocrine carcinoma of uncertain primary[J].Nucl Med Mol Imaging, 2013, 47(2): 146-147.DOI:10.1007/s13139-012-0190-4.

[6]

Hsieh TC, Wu YC, Sun SS, et al.Rare breast and adrenal gland metastases from small-cell neuroendocrine carcinoma of uterine cervix[J].Clin Nucl Med, 2012, 37(3): 280-283.DOI:10.1097/RLU.0b013e31823ea6c4.

[7]

赵红光, 徐松柏, 关锋, 等.原发性肝脏神经内分泌肿瘤¹⁸F-FDG PET/CT显像二例[J].中华核医学与分子影像杂志, 2015, 35(2): 149-151.DOI:10.3760/cma.j.issn.2095-2848.2015.02.017.
Zhao HG, Xu SB, Guan F, et al.Two cases of ¹⁸F-FDG PET/CT imaging with primary liver neuroendocine tumor[J].Chin J Nucl Med Mol Imaging, 2015, 35(2): 149-151. doi: 10.3760/cma.j.issn.2095-2848.2015.02.017.

[8]

Kaira K, Murakami H, Endo M, et al.Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors[J].Anticancer Res, 2013, 33(10): 4219-4228..

[9]

Tlostanova MS, Petrun′kin AM.Sensitivity of PET with ¹⁸F-fluorodesoxyglucose in the diagnosis of neuroendocrine tumors of the lungs[J].Vopr Onkol, 2013, 59(4): 505-508.

[10]

段钰, 李斌, 高卉, 等.神经内分泌肿瘤PET/CT的应用现状与进展[J].国际放射医学核医学杂志, 2013, 37(3): 186-192.DOI:10.3760/cma.j.issn.1673-4114.2013.03.014.
Duan Y, Li B, Gao H, et al.Application status and progress of PET/CT in neuroendocrine tumors[J].Int J Radiat Med Nucl Med, 2013, 37(3): 186-192. doi: 10.3760/cma.j.issn.1673-4114.2013.03.014.

[11]

Pagano M, Asensio SN, Zanelli F, et al.Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report[J/OL].Clin Breast Cancer, 2014, 14(5): e99-e101[2016-05-27].http://www.sciencedirect.com/science/article/pii/S1526820914000822.DOI: 10.1016/j.clbc.2014.03.001.

[12]

Frank GA, Danilova NV, Andreeva L, et al.WHO classification of tumors of the breast, 2012[J].Arkh Patol, 2013, 75(2): 53-63.

[13]

Leong PM, Lin M, Fowler AR.Three synchronous tumours identified by FDG-PET/CT[J].Med J Aust, 2009, 191(5): 275.DOI:10.1111/j.1365-2966.2011.18381.x.

[14]

Bural GG, Muthukrishnan A, Oborski MJ, et al.Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors[J].Mol Imaging Radionucl Ther, 2012, 21(3): 91-96.DOI:10.4274/Mirt.80299.

[15]

Schmidt M, Eschner W, Dietlein M, et al.Established nuclear medicine techniques for tumour diagnosis(tumour SPECT): can they still compete with ¹⁸F-FDG-PET?[J].Nuklearmedizin, 2005, 44(1): 37-48.DOI:10.1267/NUKL05010037.

[16]

孙达, 陈伟君.乳腺专用伽玛显像(BSGI)技术的最新进展[J].中国医疗器械杂志, 2015, 39(2): 108-112.DOI:10.3969/j.issn.1671-7104.2015.02.009.
Sun D, Chen WJ.Current development of Breast-Speciifc gamma imaging(BSGI)technique[J].Chin J Med lnstrum, 2015, 39(2): 108-112. doi: 10.3969/j.issn.1671-7104.2015.02.009.

[17]

谭辉, 张一秋, 石洪成.核医学乳腺专用显像仪在乳腺癌诊疗中的应用[J].中华核医学与分子影像杂志, 2014, 34(1): 73-75.DOI:10.3760/cma.j.issn.2095-2848.2014.01.024.
Tan H, Zhang YQ, Shi HC.The application of breast specific gamma imaging and positron emission mammography in the diagnosis and therapy of breast cancer[J].Chin J Nucl Med Mol Imaging, 2014, 34(1): 73-75. doi: 10.3760/cma.j.issn.2095-2848.2014.01.024.